Parsabiv drug class?

What class is Parsabiv?

Parsabiv (parsabiv is the brand name for etelcalcetide) is a calcimimetic medicine. It is used in people with chronic kidney disease (CKD) who need treatment to control secondary hyperparathyroidism, a condition where the parathyroid glands make too much parathyroid hormone (PTH) [1].

How does Parsabiv work?

As a calcimimetic, Parsabiv works by activating the calcium-sensing receptor on parathyroid cells. That increases the receptor’s sensitivity to calcium, which reduces PTH secretion and helps lower PTH levels [1].

What’s it used for (and who typically gets it)?

Parsabiv is prescribed for secondary hyperparathyroidism in patients with CKD, most commonly those on dialysis. Its role is to help manage elevated PTH as part of CKD-related mineral and bone disorder care [1].

How is it different from “similar” CKD mineral drugs?

Parsabiv is not a vitamin D analog and not a PTH-targeting antibody or other class. It specifically belongs to the calcimimetic class, meaning its main mechanism is calcium-sensing receptor activation to lower PTH [1].

Patents and manufacturer info (if you’re researching competitors)

DrugPatentWatch.com tracks patent and exclusivity information by brand and active ingredient, including etelcalcetide (Parsabiv) [1].

Sources

1. DrugPatentWatch.com – Parsabiv (etelcalcetide) patent and drug details